Get started
Author

David A. Stock

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
2019 · Robert Croop, Peter J Goadsby, et al. · The Lancet · 404
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
2019 · Richard B. Lipton, Robert Croop, et al. · New England Journal of Medicine · 400
PDF
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
2020 · Robert Croop, Richard B Lipton, et al. · The Lancet · 362
BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial
2013 · Ronald Marcus, Peter J Goadsby, et al. · Cephalalgia · 296
4-Thiazolidinones: novel inhibitors of the bacterial enzyme murB
2000 · Charles J Andres, Joanne J Bronson, et al. · Bioorganic & Medicinal Chemistry Letters · 222
BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents
2000 · Brett S. Robinson, Keith A. Riccardi, et al. · Antimicrobial Agents and Chemotherapy · 199
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
2023 · Richard B Lipton, Robert Croop, et al. · The Lancet Neurology · 157
In Vitro Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068
2012 · Beata Nowicka-Sans, Yi-Fei Gong, et al. · Antimicrobial Agents and Chemotherapy · 138
In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632
2000 · Yi-Fei Gong, Brett S. Robinson, et al. · Antimicrobial Agents and Chemotherapy · 131
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
2022 · Robert Croop, Jennifer Madonia, et al. · Headache The Journal of Head and Face Pain · 108
An Empirical Process for the Design of High-Throughput Screening Deck Filters
2006 · Bradley C. Pearce, Michael J. Sofia, et al. · Journal of Chemical Information and Modeling · 95
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
2023 · Shengyuan Yu, Byung-Kun Kim, et al. · The Lancet Neurology · 70
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
2015 · Jacob P Lalezari, Gulam H Latiff, et al. · The Lancet HIV · 68
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
2017 · Max Lataillade, Nannan Zhou, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 51
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
2018 · Javier Morales-Ramirez, Johannes R. Bogner, et al. · PLoS ONE · 42
PDF
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication
1996 · C A Deminie, C M Bechtold, et al. · Antimicrobial Agents and Chemotherapy · 42
PDF
Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Antiretroviral-Experienced Subjects: Week 48 Analysis of AI438011, a Phase IIb, Randomized Controlled Trial
2016 · the AI438011 study team, Melanie Thompson, et al. · Antiviral Therapy · 31
PDF
Best Practices in Compound Management for Preserving Compound Integrity and Accurately Providing Samples for Assays
2009 · Sandra L. Matson, Moneesh Chatterjee, et al. · SLAS DISCOVERY · 31
PDF
P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects
2022 · Rajinder Bhardwaj, Julie L. Collins, et al. · Clinical Pharmacology in Drug Development · 27
Strain-related Differences in Urine Composition of Male Rats of Potential Relevance to Urolithiasis
2009 · Sarah H. Tannehill-Gregg, Mark A. Dominick, et al. · Toxicologic Pathology · 25
Soluble Aβ and cognitive function in aged F-344 rats and Tg2576 mice
2006 · M LINDNER, J HOGAN, et al. · Behavioural Brain Research · 19
A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults
2021 · Robert Croop, Andrea Ivans, et al. · Cephalalgia Reports · 18
Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.
2006 · Mark D. Lindner, Clotilde Bourin, et al. · Experimental and Clinical Psychopharmacology · 17
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial
2015 · Samir K Gupta, Grace A McComsey, et al. · The Lancet HIV · 13
Safety profile of HIV‐1 attachment inhibitor prodrug BMS‐663068 in antiretroviral‐experienced subjects: week 24 analysis
2014 · Jacob Lalezari, Gulam H Latiff, et al. · Journal of the International AIDS Society · 6
PDF
Works count: 52
Citation count: 3,007
H-index: 20
I10-index: 24
Year
Topic
Type